<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155791</url>
  </required_header>
  <id_info>
    <org_study_id>PROS0033</org_study_id>
    <secondary_id>SU-05122010-6002</secondary_id>
    <secondary_id>17356</secondary_id>
    <nct_id>NCT01155791</nct_id>
  </id_info>
  <brief_title>Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer</brief_title>
  <official_title>A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandy Srinivas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing&#xD;
      prostate cancer. This idea is based on data from our laboratory showing that 1) prostate&#xD;
      cancer cells are more sensitive to Selenium (Sodium Selenite)-induced apoptosis than normal&#xD;
      prostate epithelial cells, 2) Selenite induces significant growth inhibition of well&#xD;
      established prostate cancer tumors in mice at doses that have no detectable toxicity, and 3)&#xD;
      Selenite disrupts AR signaling, and that the inhibition of AR expression and activity by&#xD;
      Selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1. Altogether, these&#xD;
      findings suggest that Selenium may be useful in a variety of potential indications in the&#xD;
      natural history of prostate cancer, including both hormone sensitive and castrate resistant&#xD;
      prostate cancer, as a single agent, or in combination with radiation, chemotherapy or&#xD;
      conventional hormone therapy. Selenite is a potential novel inhibitor of AR expression and&#xD;
      function in prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of the combination sodium selenite and docetaxel after 4 cycles of combination therapy using the NCI Common Toxicity Criteria v3.0 grading system for adverse events</measure>
    <time_frame>after 4 cycles of combination therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD)</measure>
    <time_frame>1 cycle</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Urologic Neoplasms</condition>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>combination sodium selenite and docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV 75 mg/m2</description>
    <arm_group_label>combination sodium selenite and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biosyn</intervention_name>
    <description>IV dosage varies</description>
    <arm_group_label>combination sodium selenite and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5mg, orally</description>
    <arm_group_label>combination sodium selenite and docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          2. Castration-resistant prostate cancer requires the following 3 criteria:&#xD;
&#xD;
               -  Failure of first line bilateral orchiectomy or therapy with an LHRH agonist,&#xD;
&#xD;
               -  A rising PSA on 3 consecutive occasions at least 1 week apart (but not limited to&#xD;
                  the 30 day screening period), AND&#xD;
&#xD;
               -  A castrate level of testosterone (&lt;50ng/dL)&#xD;
&#xD;
          3. PSA doubling time (PSADT) &gt; 1 months&#xD;
&#xD;
          4. Failure on docetaxel chemotherapy as defined by a rising PSA .&#xD;
&#xD;
          5. A minimum PSA of 2 ng/mL&#xD;
&#xD;
          6. Age &gt;=18 years&#xD;
&#xD;
          7. Life expectancy greater than 6 months&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 or Karnofsky&#xD;
             performance status &gt;=80%&#xD;
&#xD;
          9. Bone metastases will be allowed&#xD;
&#xD;
         10. The subject has a QTcB (Bazett corrected) or QTcF (Frederica corrected) &lt; 470 msec.&#xD;
&#xD;
         11. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
         12. Willingness to stay on docetaxel chemotherapy despite rising PSA level.&#xD;
&#xD;
        Exclusion Criteria:1. Radiotherapy for prostate cancer within 28 days prior to Day 1.&#xD;
&#xD;
        2. More than 1 prior chemotherapy&#xD;
&#xD;
        3. Inadequate organ function, as evidenced by any of the following at screening:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1500/uL&#xD;
&#xD;
          -  Platelet count &lt;= 100 x 10^9/L&#xD;
&#xD;
          -  Total bilirubin &gt;= ULN&#xD;
&#xD;
          -  AST, and/or ALT &gt; 1.5 x the upper limit of normal (ULN) with a concomitant alkaline&#xD;
             phosphastase &gt;2.5 X ULN&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
             4. Men with reproductive potential who do not agree to use an accepted and effective&#xD;
             method of contraception during the study treatment period and for at least 3 months&#xD;
             after completion of the study treatment.&#xD;
&#xD;
             5. History of other malignancies within 5 years prior to Day 1 except for tumors with&#xD;
             a negligible risk for metastasis or death, such as adequately controlled basal cell&#xD;
             carcinoma, squamous-cell carcinoma of the skin, or early-stage bladder cancer&#xD;
&#xD;
             6. Current, recent (within 4 weeks of the first infusion of this study), or planned&#xD;
             participation in an experimental drug study.&#xD;
&#xD;
             7. Known or prior treated brain metastases.&#xD;
&#xD;
             8. History of hypersensitivity to docetaxel&#xD;
&#xD;
             9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure ,unstable angina pectoris, cardiac&#xD;
             arrhythmia, significant vascular disease (e.g. aortic aneurysm, aortic dissection),&#xD;
             symptomatic peripheral vascular disease, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements.&#xD;
&#xD;
             10. History of myocardial infarction or unstable angina within 6 months prior to study&#xD;
             enrollment&#xD;
&#xD;
             11. History of stroke or transient ischemic attack within 6 months prior to study&#xD;
             enrollment 12. The subject is known to be positive for the human immunodeficiency&#xD;
             virus (HIV) and is receiving antiretroviral 12. Willingness to stay on docetaxel&#xD;
             chemotherapy despite rising PSA level.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sandy Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandy Srinivas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

